3rd March 2016
CERTIFICATES OF PHARMACEUTICALS PRODUCTS (COPP) CONFIRMING WHO GUIDELINES
The company has received "Certificates of Pharmaceuticals Products" (COPP) for manufacturing facilities of following products in its exiting Multiple Purpose Plant conforming to the WHO guidelines:
(1) Ibuprofen IP/BP/USP/Ph.Eur./JP
(2) Lamotrigine IP/BP/USP/Ph.Eur.
from, Food & Drugs Administration, Punjab. This will facilitate the company to broaden its presence in export market.
Ibuprofen is, a non-steroidal anti-inflammatory drug (NSAID), used for the treatment of various types of pains and Lamotrigine is, an anti-convulsant drug, used for the treatment of epileptic seizures .
The company is already having US Food and Drug Administration (USFDA) and European Directorate for the Quality of Medicines & HealthCare (EDQM) approved Ibuprofen manufacturing facilities.